Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
International Journal of Cancer|March 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)Fabian Acker, Katharina Wenger, Martin Reck, et al.
Annals of Hematology|March 3, 2019
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropeniaCornelius F Waller, Gopinath M Ranganna, Eduardo J Pennella, et al.
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 9, 2023
Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trialsIlinca Popp, Rianne D W Vaes, Lotte Wieten, et al.
Diagnostics (Basel, Switzerland)|August 5, 2020
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient ManagementJulius Wehrle, Ulrike Philipp, Martina Jolic, et al.
Oncology Research and Treatment|May 24, 2014
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, GermanyDieter Hörsch, Kurt W Schmid, Martin Anlauf, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Breast (Edinburgh, Scotland)|April 23, 2021
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trialHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.
Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.
Cancers|November 18, 2020
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan TrialEleni Gkika, Stefan Lenz, Tanja Schimek-Jasch, et al.
Pageof 9